Point72 Asset Management L.P. Raises Holdings in Sangamo Therapeutics, Inc. (SGMO)

Point72 Asset Management L.P. lifted its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 93.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 693,300 shares of the biopharmaceutical company’s stock after acquiring an additional 335,595 shares during the quarter. Point72 Asset Management L.P. owned about 0.82% of Sangamo Therapeutics worth $10,400,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Sangamo Therapeutics by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after acquiring an additional 384,031 shares in the last quarter. State Street Corp boosted its stake in shares of Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after acquiring an additional 636,296 shares in the last quarter. RA Capital Management LLC bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth about $11,000,000. Northern Trust Corp boosted its stake in shares of Sangamo Therapeutics by 4.9% during the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock worth $8,341,000 after acquiring an additional 44,656 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Sangamo Therapeutics by 3.1% during the 1st quarter. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company’s stock worth $3,296,000 after acquiring an additional 19,331 shares in the last quarter. Institutional investors own 64.35% of the company’s stock.

In related news, Director William R. Ringo sold 31,000 shares of the stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares in the company, valued at approximately $456,966. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Saira Ramasastry sold 5,000 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at approximately $73,350. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,433 shares of company stock valued at $1,309,466. 5.50% of the stock is owned by corporate insiders.

Several analysts have recently issued reports on SGMO shares. Wells Fargo & Company reiterated an “outperform” rating and set a $30.00 price target (up previously from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Jefferies Group reiterated a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research note on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, November 15th. Finally, Wedbush reiterated a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $17.83.

Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) opened at $16.35 on Friday. Sangamo Therapeutics, Inc. has a 52 week low of $2.85 and a 52 week high of $18.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same quarter in the prior year, the company earned ($0.27) EPS. The firm’s revenue for the quarter was up 333.0% compared to the same quarter last year. equities research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.73 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/12/16/point72-asset-management-l-p-raises-holdings-in-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

What are top analysts saying about Sangamo Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sangamo Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit